Systems, methods and devices for in vivo monitoring of a localized response via a radiolabeled analyte in a subject
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-051/00
A61K-049/00
출원번호
US-0127207
(2002-04-22)
발명자
/ 주소
Suddarth,Steven
Scarantino,Charles W.
Black,Robert D.
출원인 / 주소
Sicel Technologies, Inc.
대리인 / 주소
Myers Bigel Sibley &
인용정보
피인용 횟수 :
46인용 특허 :
143
초록▼
Methods, systems, devices and computer program products monitor in vivo detected radiation in a target localized site within a subject, over a selected time period, to do one or more of: (a) quantify a radiation dose received at a local site; (b) assess bioreceptiveness to a particular treatment tim
Methods, systems, devices and computer program products monitor in vivo detected radiation in a target localized site within a subject, over a selected time period, to do one or more of: (a) quantify a radiation dose received at a local site; (b) assess bioreceptiveness to a particular treatment time or type; (c) evaluate the pharmacokinetics of a radiolabeled analyte corresponding to a non-radiolabeled analyte; (d) monitor or evaluate metabolic activity; or (e) evaluate a tumor prior to or after a therapeutic treatment.
대표청구항▼
That which is claimed is: 1. A method for determining whether to administer a therapeutic amount of a chemotherapeutic drug for tumor treatment by determining an in vivo localized uptake response in solid tissue in a patient, comprising the steps of: positioning at least one sensor in vivo in solid
That which is claimed is: 1. A method for determining whether to administer a therapeutic amount of a chemotherapeutic drug for tumor treatment by determining an in vivo localized uptake response in solid tissue in a patient, comprising the steps of: positioning at least one sensor in vivo in solid tissue in a region of interest in the body of the patient; administering a test dose of a C-14 radiolabeled chemotherapeutic drug to the patient; detecting a signal from the at least one sensor corresponding to the radiation in the region of interest in the patient based on the administering step; monitoring the signal over time to determine a localized uptake response in the solid tissue of the patient based on the administered test dose; and determining whether to administer a therapeutic amount of a non-radiolabled version of the chemotherapeutic drug based on the determined localized uptake response to the test dose. 2. A method according to claim 1, further comprising: wirelessly relaying the data to an external reader; and processing the relayed signal to electronically generate a time dependent measurement profile of radioactivity in localized solid tissue to identify at least one predictor variable of interest to assess the drug uptake response in the solid tissue. 3. A method according to claim 1, wherein said determining step determines whether uptake and retention of the radiolabeled test dose in the localized solid tissue is above a predetermined threshold level. 4. A method according to claim 3, wherein said determining step determines the rate of the increase and decay in the signal strength over time. 5. A method according to claim 1, wherein said determining step determines at least one of the following; the amount of time the detected signal remains above a threshold level, the time the signal takes to reach a peak level, the time the signal takes to decay to below a threshold value, and the rate of decay from the peak to the threshold value. 6. A method according to claim 1, wherein said monitoring step monitors, over a period of at least about 15 minutes from the time said administering step is initiated, and wherein said determining step determines at least one kinetic and/or static predictor variable associated with the uptake response of the radiation in the localized solid tissue, the predictor variable including at least one of the following: (a) a time at which a detected peak radiation occurs; (b) biological 쩍 life of the detected radiation; (c) rate of increase of detected radiation; (d) rate of decrease of detected radiation; (e) a time at which the detected radiation falls a predetermined amount below the peak detected value; (f) a duration of time that the detected radiation signal increases in strength; and (g) a time during the monitored period when the detected radiation signal begins to decay. 7. A method according to claim 1, wherein the test dose is administered to the subject locally proximate to the region of interest. 8. A method according to claim 1, wherein the test dose is administered to the subject directly to the region of interest. 9. A method according to claim 1, wherein the test dose is administered to the subject systemically. 10. A method according to claim 1, wherein said determining step comprises generating a patient specific predictive treatment outcome of a planned drug therapy based on the monitored behavior of the test dose. 11. A method according to claim 1, wherein the sensor is implanted in solid tissue at a tumor treatment site, and wherein said determining step comprises evaluating radiation emitted from the C-14 radiolabeled test dose in the localized solid tissue to predict the likelihood of the respective patient having a favorable response to a known chemotherapeutic to thereby provide a patient-specific oncologic treatment evaluation. 12. A method according to claim 11, wherein the tumor treatment site comprises cancerous and/or precancerous cells, and wherein said monitoring step comprises determining cancer cell sensitivity and/or receptiveness to the radiolabeled test dose. 13. A method according to claim 1, wherein the administered radiolabeled test dose comprises C-14 labeled glucose. 14. A method according to claim 1, wherein the administered radiolabeled test dose comprises a C-14 labeled glucose derivative, wherein the glucose derivative is selected so that it has a modified glucose molecule chemical structure that is biocompatible and can be bio-chemically processed by the body. 15. A method according to claim 1, wherein the administered radiolabeled test dose comprises C-14 labeled 2-deoxyglucose. 16. A method according to claim 1, wherein the administered radiolabeled test dose comprises C-14 labeled dextraglucose. 17. A method according to claim 1, wherein the administered C-14 radiolabeled test dose comprises C-14 labeled 5-FU. 18. A method according to claim 1, further comprising evaluating metabolic activity in the subject based on data collected during said monitoring step. 19. A method according to claim 1, wherein said sensor is positioned in solid tissue spatially proximate a tumor site, and wherein said administering step is first carried out at a time which is proximate to a first planned therapeutic cancer treatment, said method further comprising: administering a second test dose of the C-14 radiolabeled chermotherapeutic drug after the first test dose and after after administering a therapeutic treatment to monitor changes in cell kinetics following a therapeutic treatment. 20. A method according to claim 19, further comprising the step of selecting a subsequent therapeutic treatment type based on said determining step. 21. A method according to claim 1, further comprising identifying at least one type of known cancer treatment as being unlikely to be clinically effective for the respective patient in generally real-time based on said monitoring and determining steps. 22. A method according to claim 1, wherein the step of positioning is carried out so that at least one sensor is positioned in the body such that at least one sensor resides in solid tissue proximate to and/or in a cancerous tumor site. 23. A method according to claim 22, wherein the step of positioning is carried out so that the sensor is chronically implanted in the subject. 24. A method according to claim 23, wherein the sensor is a unitary body implantable sensor configured to detect radiation in at least one of a director indirect mode of detection and wirelessly communicate the detected radiation data to an externally located reader. 25. A method according to claim 23, wherein the sensor includes a sensor probe body connected to and spaced apart from a processor body, and wherein the step of positioning comprises implanting the sensor probe body at a first location proximate to or in the tumor site so that it can detect radiation in a direct and/or indirect radiation detection mode and implanting the processor body at a second subcutaneous location proximate normal tissue, the second location being spaced apart from the first location. 26. A method according to claim 1, wherein the at least one sensor is a plurality of sensors, each positioned in different locations in the body of the subject. 27. A method according to claim 1, wherein the test dose of the C-14 radiolabeled chemotherapeutic drug comprises an antibody for treating cancer. 28. A method according to claim 1, wherein said at least one sensor is a plurality of sensors configured to detect the emitted radiation from the test dose at a plurality of different solid tissue locations in vivo within the region of interest to determine the biokinetics of the tissue at different positions thereof. 29. A method according to claim 1, wherein the step of positioning is carried out so that at least one sensor is positioned proximate to cancerous tissue and another sensor is positioned proximate to normal tissue, and wherein said determining step comprises determining uptake in both normal and cancerous tissue. 30. A method according to claim 1, wherein said at least one sensor is implanted in solid tissue in the target region of interest and configured to operate wirelessly. 31. A method according to claim 1, wherein the radiolabeled test dose is is a radiolabeled version of a chemotherapeutic drug undergoing clinical evaluation, and wherein the determining step comprises generating a patient-specific time dependent response profile for determining whether the pharmaceutical product reaches the region of interest and/or the pharmacodynamics and/or pharmacokinetics thereof. 32. A method according to claim 1, wherein said monitoring step is carried out such that the radioactivity in the region of interest is monitored for a period of at least about 15 minutes, and wherein the determining step comprises predicting whether a therapeutic amount of the non-radiolabeled version of the chemotherapeutic agent is likely to be clinically effective for the particular subject based on said determining step and a priori data that defines at least one predetermined predictor variable associated with the uptake response. 33. A method according to claim 1, wherein said detecting step is at least periodically performed over a period of time extending for at least between about 0.25-24 hours. 34. A method according to claim 1, wherein said determining step identifies the biological 쩍 life of the test dose in the solid tissue. 35. A method according to claim 1, wherein said monitoring and/or determining steps determine the radiation activity in the solid tissue at a plurality of points in time and then determines at least one of the pharmacokinetic, the pharmacodynamic, and/or the biokinetic response to the radiolabeled test dose in solid tissue in the region of interest. 36. A method according to claim 1, wherein the radiolabeled test dose comprises a known anti-cancer chemotherapeutic drug with a priori data associating clinical efficacy to dose, retention and/or uptake of the anti-cancer drug at a tumor treatment site. 37. A method according to claim 1, wherein the determining the response profile comprises determining whether a tumor site is taking up and/or retaining the radiolabeled test dose. 38. A method according to claim 1, wherein the monitoring and determining are carried out to determine whether the radiation from the radiolabeled analyte exhibits a 쩍 life greater than about 15 minutes at a target localized tumor treatment site. 39. A method for predicting, on a patient-specific basis, a likelihood of response to a known chemotherapeutic agent in a tumor site of a respective patient, comprising: chronically positioning at least one sensor in vivo in solid tissue proximate a tumor site in a patient's body; administering a test dose of a C-14 radiolabeled chemotherapeutic agent; detecting in vivo from the at least one sensor a signal over time corresponding to radiation proximate the tumor site in response to the administering step; relaying the detected radiation signal to a location external of the patient's body; determining a patient-specific in vivo uptake response of the C-14 radiolabeled test dose in solid tissue proximate the tumor site based on the relayed radiation signal; and determining whether to administer a therapeutic amount of a non-radiolabeled version of the chemotherapeutic agent based on the determined uptake response. 40. A method according to claim 39, wherein the determining step comprises comparing at least one predetermined predictor parameter associated with the uptake response in a patient-specific response profile to a corresponding at least one a priori predictor standard indicating the C-14 radiolabeled test dose is retained at or above a target level in the solid tissue proximate the tumor site for a target time. 41. A method according to claim 40, wherein the at least one predictor parameter comprises a C-14 half-life at the tumor site that is above about 15 minutes. 42. A method according to claim 39, the method further comprising administering the therapeutic dose amount of the non-radiolabeled chemotherapeutic agent to the patient if a favorable response is predicted by said determining whether to administer step. 43. A method according to claim 39, wherein the patient is a human, and wherein the determining whether to administer step comprises evaluating the patient uptake response to determine a likely treatment outcome of the corresponding therapeutic amount of the non-radiolabeled chemotherapeutic agent based on the monitored patient-specific uptake behavior of the radiolabeled test dose in the patient. 44. A method according to claim 39, wherein the administered C-14 labeled test dose of the chemotherapeutic agent comprises C-14 labeled glucose. 45. A method according to claim 39, wherein the administered C-14 labeled test dose of the chemotherapeutic agent comprises a C-14 labeled glucose derivative, wherein the glucose derivative is selected so that it has a modified glucose molecule chemical structure that is biocompatible and can be bio-chemically processed by the body. 46. A method according to claim 39, wherein the administered C-14 labeled test dose of the chemotherapeutic agent comprises C-14 labeled 2-deoxyglucose. 47. A method according to claim 39, wherein the administered C-14 labeled test dose of the chemotherapeutic agent comprises C-14 labeled dextraglucose. 48. A method according to claim 39, wherein the administered C-14 test dose comprises C-14 labeled 5-FU. 49. A method according to claim 39, wherein the administered C-14 test dose comprises a C-14 labeled antibody. 50. A method according to claim 39, wherein the determining step comprises generating a time-dependent patient uptake response profile.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (143)
Benjamin John D. (Malvern GB2) Mears Adrian L. (Cheltenham GB2) White John C. (Lincoln GB2), Active silicon implant devices.
Halleck Michael D. (Northglenn CO) James Donald N. (Estes Park CO) Halleck Michael E. (Longmont CO), Apparatus and method for remote monitoring of physiological parameters.
Olson Karl W. (Worthington OH) Thurston Marlin O. (Columbus OH), Apparatus and system for detecting and locating photon emissions with remote switch control.
Sperinde Johnie M. (San Jose CA) Goldring Stanley D. (Cupertino CA) Miller Dean T. (Portola Valley CA), Apparatus for determining oxygen saturation levels in blood.
Cox Timothy J. (Lake Jackson TX) Armstrong Randolph K. (Missouri City TX), Apparatus for high speed data communication between an external medical device and an implantable medical device.
Policastro Charles J. (2122 Old Forde Way Lansdale PA 19446) Dougherty Edmond J. (Philadelphia PA) Dowling Martin J. (Haddonfield NJ), Apparatus for monitoring, storing and transmitting detected physiological information.
Fenzlein Paul-Gerhard (Elsa-Brandstrmstrasse 33 D-8500 Nrnberg 80 DEX) Anderer Wolfgang (Aurachtal DEX), Apparatus for the determination of medical, electro-chemical measured values relevant to organic or metabolic functions.
Harrison Michael R. (San Francisco CA) Jennings Russell W. (Pacifica CA), B\method for monitoring fetal characteristics by radiotelemetric transmission.
Steffel Charles R. (Munroe Falls OH) Taylor Bruce C. (Kent OH), Circuit and method for the radiotelemetry of esophageal pH in an ECG radiotelemetry system.
Gough David A. (Cardiff CA) Lucisano Joseph Y. (La Jolla CA) Armour Jon C. (La Jolla CA) McKean Brian D. (San Diego CA), Complete glucose monitoring system with an implantable, telemetered sensor module.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Brockway Brian P. (Minneapolis MN) Mills Perry A. (Roseville MN) Miller Jonathan T. (St. Paul MN), Device for chronic measurement of internal body pressure.
Schulman Joseph H. (Santa Clarita CA) Rule ; III Orville R. (Los Angeles CA) Whitmoyer David I. (Los Angeles CA) Lebel Ronald J. (Sherman Oaks CA) Lucisano Joseph Y. (Saugus CA) Mann Alfred E. (Bever, Glucose monitoring system.
Halperin Louis E. (St. Paul MN) Lee Brian B. (Golden Valley MN) Roline Glenn M. (Anoka MN) Varrichio Anthony J. (Flanders NJ), Implantable capacitive absolute pressure and temperature monitor system.
Halperin Louis E. (St. Paul MN) Miesel Keith A. (St. Paul MN) Ufford Keith A. (Chisago City MN) Svensk James R. (Coon Rapids MN) Patrick Timothy (South St. Paul MN) Hassler Beth A. (White Bear Lake M, Implantable capacitive absolute pressure and temperature sensor.
Larson ; Jr. Carl O. ; Smith James S. ; Chapman John H. ; Slimon Scot A. ; Trahan John D. ; Brozek Robert J. ; Franco Alberto ; McGarvey John J. ; Rosen Marvin E. ; Pasque Michael K., Implantable device monitoring arrangement and method.
Bessman Samuel P. (2025 Zonal Ave. Los Angeles CA 90033) Layne Ennis C. (9128 Huntington Dr. San Gabriel CA 91775) Thomas Lyell J. (1900 Pelican Ave. San Pedro CA 90732), Implantable glucose sensor.
Marchosky Jose A. (Creve Couer MO) Alek Robert B. (Ellisville MO) Moran Christopher (Creve Coeur MO) Rutledge Raymond E. (Ballwin MO), Implantable hyperthermia device and system.
Prutchi David (Lake Jackson TX) Paul Patrick J. (Lake Jackson TX), Implantable medical device with enclosed physiological parameter sensors or telemetry link.
Loeb Gerald E. (90 Bagot Street Kingston ; Ontario CAX K7L 3E5 ) Schulman Joseph H. (10650 Comet Way Santa Clarita CA 91351), Implantable multichannel stimulator.
Mazziotta John C. (Beverly Hills CA) Daghighian Farhad (New York NY) Hoffman Edward J. (Van Nuys CA), Intraoperative beta probe and method of using the same.
James M. Anderson, Jr. ; Raaidah Saari-Hordhaus ; Bart C. Benedict ; Carl W. Sims ; Yuri Gurner ; Hung Anthony Pham, Ion chromatography apparatus and method for removing gas prior to sample detection.
Bergstrom Inga-Maria (Stockholm SEX) Bergstrom Mats-Johan M. (Stockholm SEX) Nilsson Kenth (Akersberga SEX), Medical field detector and telemetry unit for implants.
Markowitz Raymond S. (Elkins Park PA) Roy Robert E. (Herndon VA) Sun Xiaoguang G. (King of Prussia PA), Medical telemetry system using an implanted passive transponder.
Duffy Peter H. (Pine Bluff AR) Meehan ; III Joseph F. (Little Rock AR) Hart Ronald W. (Little Rock AR), Method and apparatus for assessing metabolic behavioral and physiological status of animals.
Marchosky J. Alexander (1501 Cerulean Dr. Creve Coeur MO 63146) Moran Christopher J. (12559 Amersham Ct. Town and Country MO 63141) Fearnot Neal E. (832 Ashland St. West Lafayette IN 47906), Method and apparatus for volumetric interstitial conductive hyperthermia.
Marchosky J. Alexander (Creve Coeur MO) Moran Christopher J. (Town and Country MO) Fearnot Neal E. (West Lafayette IN), Method and apparatus for volumetric interstitial conductive hyperthermia.
Wahl Richard L. ; Lederman Robert J., Method for detecting early atherosclerosis and vascular damage using radioactive tracers and intravascular radiation detection devices.
Abraham-Fuchs Klaus,DEX ; Gumbrecht Walter,DEX ; Hierold Christofer,DEX ; Scheiter Thomas,DEX, Method for manufacturing a combination of a pressure sensor and an electrochemical sensor.
Rumbaugh Scott H. (Lake Oswego OR) Davidson Andrew C. (Portland OR), Method for measuring the electrical and optical performance of on-wafer microwave devices.
Tarr Nicholas Garry,CAX ; Thomson Ian,CAX, Method of monitoring radiation using a floating gate field effect transistor dosimeter, and dosimeter for use therein.
Marchosky Jose A. (Creve Couer MO) Moran Christopher J. (St. Louis MO) Fearnot Neal E. (West Lafayette IN), Method, apparatus, and substance for treating tissue having neoplastic cells.
Huffman Dennis D. (Albuquerque NM) Hughes Robert C. (Albuquerque NM) Kelsey Charles A. (Albuquerque NM) Lane Richard (Galveston TX) Ricco Antonio J. (Albuquerque NM) Snelling Jay B. (Albuquerque NM) , Methods of in vivo radiation measurement.
Lefkowitz Steven M. (Walnut Creek CA) Leugers Mary A. (Midland MI) Brownell Steven J. (Midland MI) Helmer Deborah C. (Midland MI) Kastl Patrick E. (Midland MI) Chrisman Ray (Midland MI) Langvardt Pat, Miniaturized sensor for ionizing radiation.
McNulty Peter J. (Sseneca SC) Beauvais W. Joseph (Central SC) Roth David R. (Pendleton SC) Moran Wanda K. (Phoenix AZ) Reed Robert A. (Clemson SC), Passive solid state microdosimeter with electronic readout.
Synjkangas Seppo (Kykkyrintie 20 90440 Kempele FIX), Procedure and means for telemetric measuring of heartbeat and ECG signal, using a magnetic proximity field.
Thomas Edward V. (Albuquerque NM) Robinson Mark R. (Albuquerque NM) Haaland David M. (Albuquerque NM) Alam Mary K. (Albuquerque NM), Reliable noninvasive measurement of blood gases.
Thomas Edward V. (Albuquerque NM) Robinson Mark R. (Albuquerque NM) Haaland David M. (Albuquerque NM) Alam Mary K. (Cedar Crest NM), Reliable noninvasive measurement of blood gases.
Alfano Robert R. ; Alfano Scott ; Wang Quan-Zhen ; Ho Ping Pei, Remote-controllable, micro-scale device for use in in vivo medical diagnosis and/or treatment.
Morgan Wayne A. (Granada Hills CA) Mann Brian M. (Beverly Hills CA), System and method for measuring and storing parametric data pertaining to operating characteristics of an implantable me.
Mueller Jeffrey S. ; Nagle H. Troy ; Gyurcsik Ronald S. ; Kelley Arthur W., System and method for powering, controlling, and communicating with multiple inductively-powered devices.
Bryan Avron I. (26 Country Club Rd. Cocoa Beach FL 32931) Cushman Michael R. (521 Brandonwood Rd. Kingsport TN 37662), System for monitoring and reporting the operability and calibration status of a dissolved oxygen sensor.
Wyborny Paul B. (Fridley MN) Roline Glenn M. (Anoka MN) Nichols Lucy M. (Maple Grove MN) Thompson David L. (Fridley MN), Telemetry format for implanted medical device.
Wyborny Paul B. (Coon Rapids MN) Roline Glenn M. (Anoka MN) Nichols Lucy M. (Maple Grove MN) Thompson David L. (Fridley MN), Telemetry system for an implantable medical device.
Badger Christopher W. (Champaign IL) Burdette Everette C. (Champaign IL) Leech Steven C. (Tinton Falls NJ) McCarthy John F. (Champaign IL), Temperature control and analysis system for hyperthermia treatment.
Justus Brian L. (Springfield VA) Huston Alan L. (Springfield VA), Thermoluminescence radiation dosimetry using transparent glass containing nanocrystalline phosphor.
Hardy Tyrone L. (Albuquerque NM) Brynildson Laura D. (Albuquerque NM), Three-dimensional beam localization apparatus and microscope for stereotactic diagnoses or surgery mounted on robotic ty.
Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Distillation of status data relating to regimen compliance responsive to the presence and absence of wireless signals relating to one or more threshold frequencies.
Rousso, Benny; Ben-Haim, Shlomo; Melman, Haim; Bronshtine, Zohar; Zilberstien, Yoel; Nagler, Michael; Dickman, Dalia; Omer, Einav, Imaging system customization using data from radiopharmaceutical-associated data carrier.
Waynik, Jeffrey M.; Csavoy, Andrew N.; Sootsman, Keith; Solar, Matthew S.; Miller, Thomas I., Method and apparatus for positioning a guide relative to a base.
Ben-David, Gal; Zilberstien, Yoel; Kimchy, Yoav, Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures.
Kimchy, Yoav; Amrami, Roni; Bouskila, Yona; Antebi, Udi; Sidorenko, Nick; Ben-David, Gal; Zilberstein, Yoel, Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures.
Menge, Peter R., Scintillator and detector assembly including a single photon avalanche diode and a device of a quenching circuit having a same wide band-gap semiconductor material.
Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data relating to regimen compliance.
Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data relating to regimen compliance.
Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data relating to regimen compliance.
Hyde, Roderick A.; Jung, Edward K. Y.; Kare, Jordin T.; Levien, Royce A.; Lord, Robert W.; Malamud, Mark A.; Rinaldo, Jr., John D.; Sweeney, Elizabeth A.; Wood, Jr., Lowell L., Systematic distillation of status data responsive to whether or not a wireless signal has been received and relating to regimen compliance.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.